TFP
UTHR icon

Tilia Fiduciary Partners’s United Therapeutics UTHR Stock Holding History

Tilia Fiduciary Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-90
Closed -$19.9K – 474
2023
Q2 		$19.9K Hold
90
– – 0.02% 298
2023
Q1 		$20.2K Hold
90
– – 0.02% 293
2022
Q4 		$25K Hold
90
– – 0.02% 265
2022
Q3 		$19K Hold
90
– – 0.02% 291
2022
Q2 		$22K Hold
90
– – 0.02% 285
2022
Q1 		$16K Hold
90
– – 0.01% 357
2021
Q4 		$19K Buy
+90
New +$17.7K 0.02% 345

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Tilia Fiduciary Partners's UTHR Position: Q3 2023 in Review

Tilia Fiduciary Partners sold out of United Therapeutics (UTHR) in Q3 2023, closing a stake of 90 shares — an estimated $19.9K sold.

Tilia Fiduciary Partners first reported a position in UTHR in Q4 2021 and held it in 7 quarters. The position peaked at $25K in Q4 2022. 508 funds tracked by Wall St. Rank hold UTHR as of Q3 2023.

  • Tilia Fiduciary Partners reported no remaining United Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Tilia Fiduciary Partners sold 90 United Therapeutics shares in Q3 2023, an estimated $19.9K.
  • Tilia Fiduciary Partners first reported a position in United Therapeutics in Q4 2021 and held it in 7 quarters.
  • Tilia Fiduciary Partners's United Therapeutics position peaked at $25K in Q4 2022.
  • 508 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2023.

Based on Tilia Fiduciary Partners's 13F filing for Q3 2023, filed 10 Oct 2023.